Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease.

Brzezinski A, Rankin GB, Seidner DL, Lashner BA
Cleve Clin J Med. 1995 62 (5): 317-23

PMID: 7586488 · DOI:10.3949/ccjm.62.5.317

Although sulfasalazine, a 5-aminosalicylic acid (5-ASA) agent, is still the anti-inflammatory agent of choice for ulcerative colitis and Crohn's disease, newer formulations, which release drug to specific regions of the colon for maximal efficacy, also can be appropriate first-line agents. This article reviews recent clinical studies of therapy with older and newer 5-ASA formulations.

MeSH Terms (9)

Administration, Oral Aminosalicylic Acids Anti-Inflammatory Agents, Non-Steroidal Azo Compounds Delayed-Action Preparations Humans Hydrogen-Ion Concentration Inflammatory Bowel Diseases Mesalamine

Connections (1)

This publication is referenced by other Labnodes entities: